Reexamining in vivo fate of paclitaxel-loaded polymeric micelles
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Complement system in diseases · Platelet Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Polymeric mixed micelles as nanomedicines: Achievements and perspectives10.1016/j.ejpb.2016.12.019 ↗
2. Progress of drug-loaded polymeric micelles into clinical studies10.1016/j.jconrel.2014.06.042 ↗
3. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval10.1016/j.addr.2020.09.009 ↗
4. The battle of “nano” paclitaxel10.1016/j.addr.2017.02.003 ↗
5. An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional cremophor el-based paclitaxel for recurrent or metastatic her2-negative breast cancer10.4143/crt.2016.289 ↗
6. Phase I and pharmacokinetic study of genexol-pm, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies10.1158/1078-0432.CCR-03-0655 ↗
7. Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer10.1016/j.msec.2021.112186 ↗
8. Overcoming the road blocks: Advancement of block copolymer micelles for cancer therapy in the clinic10.1021/acs.molpharmaceut.7b00188 ↗
9. Polymeric micelle stability10.1016/j.nantod.2012.01.002 ↗
10. Overcoming the barriers in micellar drug delivery: Loading efficiency, in vivo stability, and micelle-cell interaction10.1517/17425240903380446 ↗
11. General considerations regarding the in vitro and in vivo properties of block copolymer micelle products and their evaluation10.1016/j.jconrel.2015.05.259 ↗
12. The blood clearance kinetics and pathway of polymeric micelles in cancer drug delivery10.1021/acsnano.8b02830 ↗
13. The protein corona leads to deformation of spherical micelles10.1002/anie.202101129 ↗
14. The in vivo fate of polymeric micelles10.1016/j.addr.2022.114463 ↗
15. Premature drug release of polymeric micelles and its effects on tumor targeting10.1016/j.ijpharm.2013.01.059 ↗
16. Development of copolymers of poly(d,l-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel10.1016/S0927-7765(99)00067-3 ↗
17. Investigation of the in vivo integrity of polymeric micelles via large stokes shift fluorophore-based fret10.1016/j.jconrel.2020.04.046 ↗
18. FRET-enabled biological characterization of polymeric micelles10.1016/j.biomaterials.2014.01.027 ↗
19. Reassessment of long circulation via monitoring of integral polymeric nanoparticles justifies a more accurate understanding10.1039/C8NH00010G ↗
20. Bioimaging of intravenous polymeric micelles based on discrimination of integral particles using an environment-responsive probe10.1021/acs.molpharmaceut.6b00705 ↗
21. Copolymer micelles and nanospheres with different in vitro stability demonstrate similar paclitaxel pharmacokinetics10.1021/mp2002939 ↗
22. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy10.1016/S0168-3659(01)00275-9 ↗
23. Controlled release of 9-nitro-20(s)-camptothecin from methoxy poly(ethylene glycol)-poly(d,l-lactide) micelles10.1088/1748-6041/3/1/015013 ↗
24. Temperature-related change in the properties relevant to drug delivery of poly(ethylene glycol)-poly(d,l-lactide) block copolymer micelles in aqueous milieu10.1016/S0168-3659(02)00147-5 ↗
25. Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(d,l-lactide) block copolymers as potential drug carrier10.1016/S0168-3659(99)00028-0 ↗
26. Facile separation of PEGylated liposomes enabled by anti-PEG scFv10.1021/acs.nanolett.1c03946 ↗
27. Anti-PEG scfv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines10.1016/j.jconrel.2020.12.047 ↗
28. Fast release of lipophilic agents from circulating peg-PDLLA micelles revealed by in vivo förster resonance energy transfer imaging10.1021/la703570m ↗
29. Clindamycin–paclitaxel pharmacokinetic interaction in ovarian cancer patients10.1007/s00280-005-0160-y ↗
30. Binding of Taxol to human plasma, albumin and alpha 1-acid glycoprotein
31. Preclinical pharmacokinetics of paclitaxel and docetaxel10.1097/00001813-199801000-00001 ↗
32. A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum10.1016/j.jim.2019.112669 ↗
33. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents10.1517/17425247.2012.720969 ↗
34. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population10.1021/acs.analchem.6b03437 ↗
35. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals10.1021/acs.analchem.6b03109 ↗
36. A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol10.1038/s41467-017-00622-4 ↗
37. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance10.1002/jps.22682 ↗
38. Particle size-dependent triggering of accelerated blood clearance phenomenon10.1016/j.ijpharm.2008.06.004 ↗
39. Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles10.1016/j.ijpharm.2012.04.049 ↗
40. Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon10.1007/s13346-018-0588-3 ↗
41. Structural insights into immunoglobulin M10.1126/science.aaz5425 ↗
42. The human IgM pentamer is a mushroom-shaped molecule with a flexural bias10.1073/pnas.0903805106 ↗
43. Insights into IgM-mediated complement activation based on in situ structures of IgM-c1-c4b10.1073/pnas.1901841116 ↗
44. Complement10.1056/NEJM200104053441406 ↗
45. Natural IgM dominates in vivo performance of liposomes10.1016/j.jconrel.2020.01.018 ↗
46. Structures of complement component C3 provide insights into the function and evolution of immunity10.1038/nature04005 ↗
47. Characterization of C3 in C3 glomerulopathy
48. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with peg allergy10.1016/j.jaci.2021.04.032 ↗
49. Pseudo-anaphylaxis to polyethylene glycol (peg)-coated liposomes: Roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions10.1021/acsnano.9b03942 ↗
50. Basophils and allergic inflammation10.1016/j.jaci.2013.07.046 ↗
51. The mystery of antibodies against polyethylene glycol (PEG) - what do we know?10.1007/s11095-016-1961-x ↗
52. Anti-peg antibodies in the clinic: Current issues and beyond pegylation10.1016/j.jconrel.2016.06.040 ↗
53. Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex10.1021/acsnano.9b07218 ↗
54. Antibody against poly(ethylene glycol) adversely affects peg-asparaginase therapy in acute lymphoblastic leukemia patients10.1002/cncr.22739 ↗
55. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C10.1056/NEJMc052880 ↗
56. Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: A review10.1080/14686996.2019.1590126 ↗
57. Co-delivery of paclitaxel and melittin by glycopeptide-modified lipodisks for synergistic anti-glioma therapy10.1039/C9NR01820D ↗
58. Deciphering protein corona by scfv-based affinity chromatography10.1021/acs.nanolett.0c04806 ↗
59. Veterinary cooperative oncology group-common terminology criteria for adverse events (VCOG-CTCAE V2) following investigational therapy in dogs and cats10.1111/vco.12677 ↗